RU98118906A - AMIDIC DERIVATIVES OR THEIR SALTS - Google Patents

AMIDIC DERIVATIVES OR THEIR SALTS

Info

Publication number
RU98118906A
RU98118906A RU98118906/04A RU98118906A RU98118906A RU 98118906 A RU98118906 A RU 98118906A RU 98118906/04 A RU98118906/04 A RU 98118906/04A RU 98118906 A RU98118906 A RU 98118906A RU 98118906 A RU98118906 A RU 98118906A
Authority
RU
Russia
Prior art keywords
amino
phenylethyl
hydroxy
ethyl
acetanilide
Prior art date
Application number
RU98118906/04A
Other languages
Russian (ru)
Other versions
RU2186763C2 (en
Inventor
Тацуя Маруяма
Такаюки Сузуки
Кенити Онда
Масахико Хаякава
Хироюки Моритомо
Тецуя Кимизука
Тецуо Мацуи
Original Assignee
Яманоути Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Яманоути Фармасьютикал Ко., Лтд. filed Critical Яманоути Фармасьютикал Ко., Лтд.
Publication of RU98118906A publication Critical patent/RU98118906A/en
Application granted granted Critical
Publication of RU2186763C2 publication Critical patent/RU2186763C2/en

Links

Claims (4)

1. Амидное производное, представленное следующей формулой:
Figure 00000001

где кольцо В представляет гетероарильную группу; Х представляет связь или низшую алкиленовую группу; R представляет атом водорода, атом галогена, низшую алкильную группу, амино группу, арил-(низшую) алкильную группу или галогенарил (низшую) алкильную группу, или его соль.1. The amide derivative represented by the following formula:
Figure 00000001

where ring B represents a heteroaryl group; X represents a bond or a lower alkylene group; R represents a hydrogen atom, a halogen atom, a lower alkyl group, an amino group, an aryl- (lower) alkyl group or a halogenaryl (lower) alkyl group, or a salt thereof. 2. Амидное производное по п. 1, представляющее (R)-4'-[2-[(2-(гидрокси-2-фенилэтил)амино] этил] -2-пиридинкарбоксанилид; (R)-2-[1-(4-хлорбензил)-1Н-имидазол-2-ил] -4'-[2-[(2-гидрокси-2-фенилэтил)амино] этил] ацетанилид; (R)-2-[1-(3,4-дихлорбензил)-1Н-тетразол-5-ил] -4'-[2-[(2-гидрокси-2-фенилэтил)амино] этил]ацетанилид; (R)-2-(2-аминотиазол-4-ил)-4'-[2-(2-гидрокси-2-фенилэтил)амино] -этил] ацетанилид; (R)-2-(2-аминопиридин-6-ил)-4'-[2-[(2-гидрокси-2-фенилэтил)амино] этил] ацетанилид; или (R)-4'-[2-[(2-гидрокси-2-фенилэтил)амино]этил]-2-(2-пиридил)-ацетанилид; или их соли. 2. The amide derivative according to claim 1, representing (R) -4 '- [2 - [(2- (hydroxy-2-phenylethyl) amino] ethyl] -2-pyridinecarboxanilide; (R) -2- [1- ( 4-chlorobenzyl) -1H-imidazol-2-yl] -4 '- [2 - [(2-hydroxy-2-phenylethyl) amino] ethyl] acetanilide; (R) -2- [1- (3,4- dichlorobenzyl) -1H-tetrazol-5-yl] -4 '- [2 - [(2-hydroxy-2-phenylethyl) amino] ethyl] acetanilide; (R) -2- (2-aminothiazol-4-yl) - 4 '- [2- (2-hydroxy-2-phenylethyl) amino] ethyl] acetanilide; (R) -2- (2-aminopyridin-6-yl) -4' - [2 - [(2-hydroxy- 2-phenylethyl) amino] ethyl] acetanilide; or (R) -4 '- [2 - [(2-hydroxy-2-phenylethyl) amino] ethyl] -2- (2-pyridyl) acetanilide; or their salts. 3. Фармацевтическое средство от сахарного диабета, отличающееся тем, что оно включает амидное производное или его соль по п. 1 в качестве активного ингредиента в терапевтически эффективном количестве. 3. A pharmaceutical agent for diabetes mellitus, characterized in that it comprises an amide derivative or a salt thereof according to claim 1 as an active ingredient in a therapeutically effective amount. 4. Фармацевтическое средство по п. 3, отличающееся тем, что оно включает амидное производное или его соль по п. 2. 4. The pharmaceutical agent according to claim 3, characterized in that it includes an amide derivative or its salt according to claim 2.
RU98118906/04A 1997-10-17 1998-10-16 Amide derivatives or their salts RU2186763C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JPHEI-9-285778 1997-10-17
JP28577897 1997-10-17

Publications (2)

Publication Number Publication Date
RU98118906A true RU98118906A (en) 2000-06-27
RU2186763C2 RU2186763C2 (en) 2002-08-10

Family

ID=17695954

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98118906/04A RU2186763C2 (en) 1997-10-17 1998-10-16 Amide derivatives or their salts

Country Status (21)

Country Link
US (1) US6346532B1 (en)
EP (1) EP1028111B1 (en)
JP (1) JP3193706B2 (en)
KR (1) KR100506568B1 (en)
CN (1) CN1136193C (en)
AR (1) AR017340A1 (en)
AT (1) ATE266639T1 (en)
AU (1) AU9462198A (en)
BR (1) BR9804500B1 (en)
CA (1) CA2305802C (en)
DE (1) DE69823858T2 (en)
DK (1) DK1028111T3 (en)
ES (1) ES2221204T3 (en)
HU (1) HU227560B1 (en)
ID (1) ID23989A (en)
NO (2) NO316673B1 (en)
PL (1) PL196510B1 (en)
PT (1) PT1028111E (en)
RU (1) RU2186763C2 (en)
TW (1) TW557295B (en)
WO (1) WO1999020607A1 (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2356197A (en) 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6498170B2 (en) 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6410734B1 (en) 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
UA82048C2 (en) 2000-11-10 2008-03-11 Эли Лилли Энд Компани Peroxisome proliferator activated receptor alpha agonists
US7342117B2 (en) * 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
WO2003042160A1 (en) 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
AU2002364291B2 (en) * 2001-12-20 2007-08-02 Merck Serono Sa Triazoles as oxytocin antagonists
CA2503570C (en) 2002-11-07 2011-04-19 Yamanouchi Pharmaceutical Co., Ltd. Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
DE102004001413A1 (en) * 2004-01-09 2005-08-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-hydroxymethyl-4-hydroxy-phenyl derivatives for the treatment of chronic obstructive pulmonary disease
WO2006014704A1 (en) * 2004-07-21 2006-02-09 Theravance, Inc. DIARYL ETHER β2 ADRENERGIC RECEPTOR AGONISTS
CN101595088B (en) 2007-01-31 2013-06-19 东丽株式会社 Benzylamine derivative or pharmaceutically acceptable acid addition salt thereof, and use thereof for medical purposes
US20100240697A1 (en) 2007-11-02 2010-09-23 Astellas Pharma Inc. Pharmaceutical composition for treating overactive bladder
EP2223690A4 (en) 2007-12-21 2011-02-23 Astellas Pharma Inc Pharmaceutical composition for ameliorating lower urinary tract symptom
DE102008014523A1 (en) * 2008-03-15 2009-09-17 Robert Bosch Gmbh heater
CA2724077C (en) * 2008-05-14 2016-04-26 Astellas Pharma Inc. Amide compound
TWI478712B (en) * 2008-09-30 2015-04-01 Astellas Pharma Inc Pharmaceutical composition for modified release
WO2010147830A2 (en) 2009-06-15 2010-12-23 Auspex Pharmaceuticals, Inc. Aminothiazole modulators of beta-3-adrenoreceptor
US20120070465A1 (en) 2010-03-29 2012-03-22 Astellas Pharma Inc. Pharmaceutical composition for modified release
US8877214B2 (en) * 2010-03-29 2014-11-04 Astellas Pharma Inc. Pharmaceutical composition for modified release
US9655885B2 (en) 2011-05-18 2017-05-23 Dr. Reddy's Laboratories Ltd. Amorphous mirabegron and processes for crystal forms of mirabegron
IN2013CN09704A (en) * 2011-05-18 2015-07-03 Reddys Lab Ltd Dr
JPWO2013147134A1 (en) 2012-03-30 2015-12-14 アステラス製薬株式会社 Mirabegron-containing pharmaceutical composition
CN103387500A (en) * 2012-05-11 2013-11-13 上海医药工业研究院 Preparation methods for mirabegron and intermediate thereof
CN104602693A (en) 2012-08-31 2015-05-06 安斯泰来制药株式会社 Orally administered medical composition
US9784726B2 (en) 2013-01-08 2017-10-10 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatment
CN103193730A (en) * 2013-04-17 2013-07-10 苏州永健生物医药有限公司 Synthesis method of mirabegron
CN103232368B (en) * 2013-04-18 2015-08-12 苏州永健生物医药有限公司 A kind of synthetic method of (R)-4-nitrophenethyl-(2-hydroxyl-2-styroyl)-t-butyl carbamate
WO2015040605A1 (en) 2013-09-23 2015-03-26 Ranbaxy Laboratories Limited Crystalline form of mirabegron
WO2015040573A1 (en) 2013-09-23 2015-03-26 Ranbaxy Laboratories Limited Mirabegron dimethyl sulphoxide solvate and its use for the treatment of overactive bladder
WO2015044965A1 (en) 2013-09-30 2015-04-02 Megafine Pharma (P) Ltd. A process for preparation of mirabegron and alpha crystalline form thereof
ITMI20131653A1 (en) * 2013-10-07 2015-04-08 Dipharma Francis Srl CRYSTALLINE FORMS OF AN ADRENERGIC AGONIST
CN104876889B (en) * 2014-02-27 2017-02-22 人福医药集团股份公司 A synthesis method of a compound
WO2015162536A1 (en) * 2014-04-22 2015-10-29 Calyx Chemicals And Pharmaceuticals Ltd. Novel process for preparation of mirabegron and it's intermediate
CN103896872A (en) * 2014-04-29 2014-07-02 黑龙江大学 Method for synthesizing mirabegron
JP6759185B2 (en) 2014-08-06 2020-09-23 インテルキム、ソシエダッド アノニマ Method for synthesizing mirabegron and its derivatives
WO2016024284A2 (en) 2014-08-07 2016-02-18 Wanbury Ltd. A process for the preparation of mirabegron and its intermediates
CN105481705A (en) * 2014-08-23 2016-04-13 南京海纳医药科技有限公司 Preparation and application of (R)-2-[[2-(4-aminophenyl)ethyl]amino]-1-phenylethyl alcohol
CA2962664A1 (en) * 2014-10-01 2016-04-07 Apotex Inc. Solid forms of mirabegron
CN104496841B (en) * 2014-11-26 2017-01-25 南京工业大学 Method for synthesizing mirabegron intermediate
EP3253741A1 (en) 2015-02-02 2017-12-13 Lupin Limited Process for preparation of polymorphic form of mirabegron
JP2018090490A (en) 2015-03-31 2018-06-14 アステラス製薬株式会社 Mirabegron-containing pharmaceutical composition
CN105111165B (en) * 2015-09-14 2017-10-31 保定博洋生物科技有限公司 A kind of preparation method of Mirabegron
EP3353156B1 (en) * 2015-09-23 2021-11-03 The General Hospital Corporation Tead transcription factor autopalmitoylation inhibitors
FR3043555B1 (en) * 2015-11-17 2019-10-25 Centre National De La Recherche Scientifique (Cnrs) MIRABEGRON FOR THE TREATMENT OF RETINAL DISEASES
EP3184516A1 (en) 2015-12-23 2017-06-28 Enantia, S.L. Crystalline inclusion complexes of mirabegron with beta-cyclodextrin
HU231124B1 (en) * 2016-02-10 2020-12-28 Egis Gyógyszergyár Zrt. Method for producing morphologically homogenous mirabegron and mirabegron monohydrochloride
WO2017186598A1 (en) 2016-04-25 2017-11-02 Synthon B.V. Modified release tablet composition comprising mirabegron
EP3448367A1 (en) 2016-04-25 2019-03-06 Synthon BV Tablets comprising mirabegron and solifenacin
GB201612165D0 (en) * 2016-07-13 2016-08-24 Atrogi Ab Combinations for the treatment of type 2 diabetes
US9988402B2 (en) 2016-08-19 2018-06-05 Purdue Research Foundation Amine-boranes bearing borane-intolerant functionalities
EP3335700A1 (en) 2016-12-13 2018-06-20 Stada Arzneimittel Ag Solid pharmaceutical oral dosage form comprising an extended release of the active ingredient comprising mirabegron
SI3360866T1 (en) 2017-02-14 2019-04-30 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Mirabegron prodrugs
KR101868438B1 (en) 2017-04-13 2018-06-20 (주) 성운파마코피아 Method for preparing amide derivatives
KR102398639B1 (en) 2017-06-20 2022-05-17 (주) 성운파마코피아 Salts of amide derivatives and method for preparing the same
WO2019013583A2 (en) 2017-07-14 2019-01-17 주식회사 대웅제약 Pharmaceutical preparation and preparation method therefor
KR101937713B1 (en) 2017-07-14 2019-01-14 주식회사 대웅제약 Pharmaceutical formulation and preparation method for the same
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
EP3694492A1 (en) 2017-10-12 2020-08-19 Synthon B.V. Modified release tablet composition comprising mirabegron
EP3292864A1 (en) 2017-10-12 2018-03-14 Synthon B.V. Modified release tablet composition comprising mirabegron
US10478399B2 (en) 2017-10-12 2019-11-19 Synthon B.V. Modified release tablet composition comprising mirabegron
KR101928987B1 (en) * 2018-08-28 2018-12-13 (주) 성운파마코피아 A New and Highly Pure Crystalline monohydrate of mirabegron, Method for Preparing or Use Thereof
CN109776373B (en) * 2019-01-29 2020-04-21 广东东阳光药业有限公司 Amide-substituted pyrrolidine amide derivatives and uses thereof
CN109734712B (en) * 2019-01-30 2020-10-20 广东东阳光药业有限公司 Aryl or heteroaryl substituted pyrrolidine amide derivatives and uses thereof
KR20200117091A (en) 2019-04-02 2020-10-14 제이투에이치바이오텍 (주) Prodrug compound of mirabegron and its medical use for treating or alleviating overactive bladder diseases
KR20210012082A (en) 2019-07-23 2021-02-03 콜마파마(주) A pharmaceutical composition comprising mirabegron and tamsulosin
CN110590699B (en) * 2019-09-29 2022-11-15 广东先强药业有限公司 Refining method of mirabegron
EP3722285B1 (en) 2020-04-08 2022-03-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Process for preparing mirabegron enacarbil
KR102333167B1 (en) 2021-05-26 2021-12-01 유니셀랩 주식회사 An efficient and mass-producible Mirabegron amorphous manufacturing method
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2965655D1 (en) * 1978-06-28 1983-07-21 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
US5223614A (en) * 1987-12-19 1993-06-29 Boehringer Ingelheim Gmbh New quaternary ammonium compounds, their preparation and use
DE3743265A1 (en) * 1987-12-19 1989-06-29 Boehringer Ingelheim Kg NEW AMMONIUM COMPOUNDS, THEIR MANUFACTURE AND USE
WO1993019861A1 (en) 1992-03-27 1993-10-14 Kawasaki Steel Corporation Method of detecting roll clearance setting error for universal rolling machines and method of rolling h-beam having favorable flange size by utilizing said method
US5451677A (en) * 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
US5614544A (en) 1993-09-14 1997-03-25 Takeda Chemical Industries, Ltd. Oxazolidinedione derivatives and their use
JP3722855B2 (en) * 1993-09-14 2005-11-30 武田薬品工業株式会社 2,4-oxazolidinedione derivative and pharmaceutical comprising the same
IL113410A (en) * 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
US5541197A (en) * 1994-04-26 1996-07-30 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
WO1998032742A1 (en) 1997-01-23 1998-07-30 Yamanouchi Pharmaceutical Co., Ltd. Novel amide derivatives and medicinal compositions thereof
JPH10218861A (en) * 1997-02-04 1998-08-18 Yamanouchi Pharmaceut Co Ltd New phenethanol derivative or its salt

Similar Documents

Publication Publication Date Title
RU98118906A (en) AMIDIC DERIVATIVES OR THEIR SALTS
JP2004532209A5 (en)
EP1400518A4 (en) Heterocyclic compound derivatives and medicines
EA201000300A1 (en) METHOD FOR SYNTHESIS OF COMPOUNDS SUITABLE FOR THE TREATMENT OF HEPATITIS C
DE69118082D1 (en) Imidazole derivatives, strong and selective angiotensin II receptor antagonists
DK1379520T3 (en) N-substituted non-aryl heterocyclic NMDA / NR2B antagonists
RU97100151A (en) DERIVATIVES OF PIPERAZINE AS ANTAGONISTS 5HT1A
CA2039056A1 (en) 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
PE20020917A1 (en) DERIVATIVES OF IMIDAZOLE AS N-METHYL-D-ASPARTATE RECEPTOR BLOCKERS
RU2002100058A (en) 1-Methylcarbapenem Crystal Derivatives
WO2001036425A3 (en) Imidazole compounds used as phosphodiesterase vii inhibitors
EP0388909A3 (en) Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
TR199801218T2 (en) N-acyl-2-substituted-4-(Benzimidazolyl-or imidazopyridinyl-substituted residues)-piperidines as tachykinin antagonists.
ATA20991A (en) NEW IMIDAZOLE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE
EP0902018A3 (en) 2-(Arylphenyl)amino-imidazoline derivatives
DE60016786D1 (en) BICYCLIC VASOPRESSINE AGONIST
PE20010954A1 (en) BENZHIMIDAZOLES, ITS PREPARATION AND ITS USE AS MEDICINES
IT1295405B1 (en) USE OF AN ANGIOTENSIN II RECEPTORAL ANTAGONIST FOR DRUG PREPARATION TO INCREASE THE SURVIVAL RATE OF
JP2005513103A5 (en)
DE69911557D1 (en) Imidazoline derivatives, their preparation and pharmaceutical compositions containing them
EP0355827A3 (en) Hydantoin derivatives
MXPA03009546A (en) Novel insecticidal azoles.
DE69812010D1 (en) 4-aminopyrrole (3,2-d) pyrimidines as antagonists of the neuropeptide Y receptor
RU2002111663A (en) AMIDE COMPOUNDS
WO1999013871A3 (en) Fused imidazole derivatives for improving oral bioavailability of pharmaceutical agents